InvestorsHub Logo
Followers 12
Posts 292
Boards Moderated 0
Alias Born 03/01/2024

Re: LEFTY1182 post# 45198

Wednesday, 04/24/2024 9:01:50 AM

Wednesday, April 24, 2024 9:01:50 AM

Post# of 49034
I agree.

Even if you assume it takes the entire OS of 2 billion shares to satisfy all warrants and notes outstanding.... essentially fully diluted.. Probably wont be near that much...

.02 would be a 40 million mrkt cap
.08 would be a 160 million mrkt cap

Considering they have an OSA program supposedly "valued" around 20 million, that assuming they are completeing some preclinical work on the new formulations in preps to launch human trials in late stages. And their promising SCI/ADHD candidate is waiting funding to continue human trials in later stages as well.

And then the pain/epilepsy candidate progressing through NIH preclinicals, which if successful as they appear confident in, would open up grant funding for human trials. Which would then be a high profile candidate that could help mitigate opioids. I've seen other preclinical pharma deals in the 10's to hundreds of million upfront, with potential milestone payments dwarfing that. Feels just like accumulating at pennies on the dollar here. But for balance, there is still plenty of risk in pharma industry, huge thresholds have to be met to advance any drug candidate. And maybe that is just simply where this is at currently. Insiders and institutional according to filings appear to be lining up with equity positions that can possibly pay off massively if their drug candidates successfully advance. Success not guaranteed but if it happens, I think we all can imagine how quickly the stock will gain traction and become one of those OTC story stocks... IMO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News